Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2006 1
2007 1
2008 7
2009 6
2010 13
2011 14
2012 10
2013 17
2014 13
2015 17
2016 22
2017 25
2018 12
2019 27
2020 35
2021 30
2022 25
2023 20
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
GRADE concept paper 8: judging the certainty of discrimination performance estimates of prognostic models in a body of validation studies.
Foroutan F, Mayer M, Guyatt G, Riley RD, Mustafa R, Kreuzberger N, Skoetz N, Darzi A, Alba AC, Mowbray F, Rayner DG, Schunemann H, Iorio A. Foroutan F, et al. Among authors: iorio a. J Clin Epidemiol. 2024 Apr 3;170:111344. doi: 10.1016/j.jclinepi.2024.111344. Online ahead of print. J Clin Epidemiol. 2024. PMID: 38579978 Free article.
Lower-dose emicizumab prophylaxis: can less be more?
Srivastava A, Iorio A. Srivastava A, et al. Among authors: iorio a. J Thromb Haemost. 2024 Apr;22(4):922-925. doi: 10.1016/j.jtha.2024.01.018. J Thromb Haemost. 2024. PMID: 38521578 No abstract available.
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Matino D, Germini F, Chan AKC, Decker K, Iserman E, Chelle P, Edginton AN, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A. Matino D, et al. Among authors: iorio a. Haemophilia. 2024 Mar;30(2):345-354. doi: 10.1111/hae.14960. Epub 2024 Feb 20. Haemophilia. 2024. PMID: 38379181
The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients.
Coffin D, Gouider E, Konkle B, Hermans C, Lambert C, Diop S, Ayoub E, Tootoonchian E, Youttananukorn T, Dakik P, Pereira T, Iorio A, Pierce GF; World Bleeding Disorders Registry Participating Investigators. Coffin D, et al. Among authors: iorio a. Res Pract Thromb Haemost. 2023 Nov 20;7(8):102264. doi: 10.1016/j.rpth.2023.102264. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193052 Free PMC article.
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.
Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettle A, Samji N, Rivard GÉ, Carcao M, Iorio A, Makris M; EUHASS and CHESS participants. Fischer K, et al. Among authors: iorio a. Res Pract Thromb Haemost. 2023 Nov 20;7(8):102265. doi: 10.1016/j.rpth.2023.102265. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193044 Free PMC article.
GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists.
Piggott T, Moja L, Jenei K, Kredo T, Skoetz N, Banzi R, Trapani D, Leong T, McCaul M, Lavis JN, Akl EA, Nonino F, Iorio A, Laurson-Doube J, Huttner BD, Schünemann HJ. Piggott T, et al. Among authors: iorio a. J Clin Epidemiol. 2024 Feb;166:111241. doi: 10.1016/j.jclinepi.2023.111241. Epub 2023 Dec 19. J Clin Epidemiol. 2024. PMID: 38123105 Free PMC article.
276 results